MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA- INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.061
https://www.valueinhealthjournal.com/article/S1098-3015(18)33361-8/fulltext
Title :
MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA- INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33361-8&doi=10.1016/j.jval.2018.09.061
First page :
Section Title :
Open access? :
No
Section Order :
7